Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (~30%) will undergo imaging with standardized intervals.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- N-Power Medicine
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Pacific Cancer Care · Monterey, CA
- Torrance Memorial Physician Network-Cancer Care · Torrance, CA
- John Muir Health · Walnut Creek, CA
Delaware · 2
- Bayhealth Cancer Center- Kent · Dover, DE
- Bayhealth Cancer Center- Sussex · Milford, DE
Idaho · 1
- Kootenai Clinic Cancer Services Coeur d'Alene · Coeur d'Alene, ID
Illinois · 1
- Northwest Oncology & Hematology · Elk Grove Village, IL
New Mexico · 1
- New Mexico Oncology Hematology Consultants · Albuquerque, NM
Texas · 1
- Oncology Consultants, P.A. · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.